Insider Trading Activity Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Insider Sold 6,110 shares of Stock

Insider Trading Activity For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)

Susan E Barrowcliffe , Insider of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) reportedly Sold 6,110 shares of the company’s stock at an average price of 22 for a total transaction amount of $134,420.00 SEC Form

Insider Trading History For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)

On 3/29/2016 Longitude Capital Partners Ii,, Major Shareholder, bought 78,504 with an average share price of $13.87 per share and the total transaction amounting to $1,088,850.48.View SEC Filing

On 5/31/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 240,000 with an average share price of $15.23 per share and the total transaction amounting to $3,655,200.00.View SEC Filing

On 9/8/2016 Mary M Rozenman, Insider, sold 30,000 with an average share price of $16.80 per share and the total transaction amounting to $504,000.00.View SEC Filing

On 10/5/2016 Mary M Rozenman, Insider, sold 25,000 with an average share price of $16.80 per share and the total transaction amounting to $420,000.00.View SEC Filing

On 11/4/2016 Mary M Rozenman, Insider, sold 24,096 with an average share price of $17.60 per share and the total transaction amounting to $424,089.60.View SEC Filing

On 3/21/2017 Warren L Desouza, CFO, sold 10,000 with an average share price of $22.95 per share and the total transaction amounting to $229,500.00.View SEC Filing

On 4/3/2017 Warren L Desouza, CFO, sold 15,000 with an average share price of $21.58 per share and the total transaction amounting to $323,700.00.View SEC Filing

Analyst Ratings For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
These are 4 Buy Ratings .
The current consensus rating for Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is Buy (Score: 3.00) with a consensus target price of $36.25 , a potential (67.44% upside)

Analyst Ratings History For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)

• On 5/16/2016 Bank of America Corporation Reiterated Rating Buy
• On 8/19/2016 Credit Suisse Group Reiterated Rating Buy with a price target of $35.00
• On 9/26/2016 JMP Securities Initiated Coverage of rating Outperform with a price target of $30.00
• On 3/22/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $38.00
• On 7/24/2017 Wedbush Reiterated Rating Outperform with a price target of $42.00

Recent Trading Activity for Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
Shares of Aimmune Therapeutics, Inc. closed the previous trading session at 21.65 down -0.35 -1.59% with 175,214 shares trading hands.